Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

P4‐053: Memory, executive, and multi‐domain subtle cognitive impairment: Clinical and biomarker finding
Bjerke, Maria , Rozycki, Martin, Weiner, Michael W. , Arnold, Steven E. , Reiman, Eric M. , Shaw, Leslie M. , Trojanowski, John Q. , Toledo, Jon B. , Chen, Kewei , Jack, Clifford R. , Davatzikos, Christos

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_17 | Pages: No page available

10.1016/j.jalz.2015.06.1758 Get It

P2‐170: Plasma ceramides predict age‐related differences in white matter microstructure
Venkatraman, Vijay , An, Yang , Bandaru, Veera Venkata Ratnam, Resnick, Susan M. , Gonzalez, Christopher E. , Landman, Bennett A , Haughey, Norman J. , Ferrucci, Luigi , Mielke, Michelle M.

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_12 | Pages: No page available

10.1016/j.jalz.2015.06.709 Get It

Novel Bone-Targeting Agent for Enhanced Delivery of Vancomycin to Bone
Albayati, Zaineb A.F., Sunkara, Manjula , Schmidt-Malan, Suzannah M., Karau, Melissa J. , Morris, Andrew J. , Steckelberg, James M., Patel, Robin , Breen, Philip J., Smeltzer, Mark S. , Taylor, K. Grant, Merten, Kevyn E., Pierce, William M., Crooks, Peter A. , Patel, Robin

Antimicrobial Agents and Chemotherapy | December 15, 2015 | Volume: 60 | Issue: 3 | Pages: 1865-1868

10.1128/aac.01609-15 | PMID 26666918 Get It

ABSTRACT We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk
López, Ana María , Pruthi, Sandhya , Perloff, Marjorie , Hsu, Chiu-Hsieh, Lang, Julie E. , Ley, Michele, Frank, Denise, Taverna, Josephine A. , Chow, H.‐H. Sherry , Boughey, Judy C.

Cancer Prevention Research | December 15, 2015 | Volume: 9 | Issue: 2 | Pages: 142-148

10.1158/1940-6207.capr-15-0322 | PMID 26667449 Get It

Abstract Aromatase inhibitors (AI) profoundly suppress estrogen levels in postmenopausal women and are effective in breast cancer prevention among high-risk postmenopausal women. Unfortunately, AI treatment is associated with undesirable side effects that limit patient acceptance for primary prevention of breast cancer. A double-blind, randomized trial was conducted to determine whether low and intermittent doses of letrozole can achieve effective estrogen suppression with a more favorable side-effect profile. Overall, 112 postmenopausal women at increased risk for breast cancer were randomized to receive letrozole at 2.5 mg once daily (QD, standard dose arm), 2.5 mg every Monday, Wednesday, and Friday (Q-MWF), 1.0 mg Q-MWF, or 0.25 mg Q-MWF for 24 weeks. Primary endpoint was suppression in serum estradiol levels at the end of letrozole intervention. Secondary endpoints included changes in serum estrone, testosterone, C-telopeptide (marker of bone resorption), lipid profile, and quality-of-life measures (QoL) following treatment. Significant estrogen suppression was observed in all dose arms with an average of 75% to 78% and 86% to 93% reduction in serum estradiol and estrone levels, respectively. There were no differences among dose arms with respect to changes in C-telopeptide levels, lipid profile, adverse events (AE), or QoL measures. We conclude that low and intermittent doses of letrozole are not inferior to standard dose in estrogen suppression and resulted in a similar side-effect profile compared with standard dose. Further studies are needed to determine the feasibility of selecting an effective AI dosing schedule with better tolerability. Cancer Prev Res; 9(2); 142–8. ©2015 AACR.
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study
Tewari, Krishnansu S. , Sill, Michael W. , Monk, Bradley J. , Penson, Richard T. , Long, Harry J., Poveda, Andrés , Landrum, Lisa M. , Brown, Jubilee , Reid, Thomas , Michael, Helen E., Moore, David H. , Leitão, Mario M.

Clinical Cancer Research | December 15, 2015 | Volume: 21 | Issue: 24 | Pages: 5480-5487

10.1158/1078-0432.ccr-15-1346 | PMID 26672085 Get It

Abstract Purpose: In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Experimental Design: Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk categories included low-risk (0–1 factor), mid-risk (2–3 factors), and high-risk (4–5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. Results: For the entire population (n = 452), high-risk patients had significantly worse OS (P < 0.0001). The HRs of death for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63–2.24], 1.11 (95% CI, 0.82–1.5), and 0.84 (95% CI, 0.50–1.42), respectively. The HRs of death for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51–1.83; P = 0.9087), 0.673 (95% CI, 0.5–0.91; P = 0.0094), and 0.536 (95% CI, 0.32–0.905; P = 0.0196), respectively. Conclusions: This is the first prospectively validated scoring system in cervical cancer. The Moore criteria have real-world clinical applicability. Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8-month increase in median OS). Clin Cancer Res; 21(24); 5480–7. ©2015 AACR.
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Mansfield, Aaron S. , Peikert, Tobias, Yi, Eunhee S. , Vasmatzis, George , Wigle, Dennis A. , Aubry, Marie Christine, Murphy, Stephen J. , Mansfield, Aaron S

Clinical Cancer Research | December 14, 2015 | Volume: 22 | Issue: 9 | Pages: 2177-2182

10.1158/1078-0432.ccr-15-2246 | PMID 26667490 Get It

Abstract Purpose: The expression of programmed cell death ligand 1 (PD-L1) provides limited predictive value in identifying patients most likely to respond to immunotherapy. As the heterogeneity of PD-L1 expression may lead to sampling error and the misclassification of PD-L1 status, we assessed the distribution of PD-L1 expression in paired, resected multifocal lung cancers. Experimental Design: PD-L1 was assessed by IHC. Paired lesions were defined as independent primaries or related lesions using mate pair next-generation sequencing. Agreement statistics were used for analysis. Results: Sixty-seven multifocal lung cancers from 32 patients were sequenced and stained for PD-L1. There was agreement of PD-L1 expression by the tumor cells in paired lesions of 20 patients and disagreement of PD-L1 expression by the tumor cells in paired lesions of 12 patients (κ = 0.01). Sequencing identified that 23 patients had independent primary lung cancers and that 9 patients had related cancers. In paired lesions of patients with independent cancers, there was agreement of PD-L1 expression by the tumor cells in 12 patients and disagreement in 11 patients (κ = 0.31). In paired lesions of patients with related lung cancers, there was agreement of PD-L1 expression by the tumor cells in 8 patients and disagreement in 1 patient (κ = 0.73). Conclusions: The expression of PD-L1 is heterogeneous among paired independent lung cancers, but there are high levels of agreement in intrapulmonary metastasis. Clin Cancer Res; 22(9); 2177–82. ©2015 AACR.
Placebo-controlled study in neuromyelitis optica—Ethical and design considerations
Cree, Bruce , Bennett, Jeffrey L. , Sheehan, Mark , Hartung, Hans-Peter, Aktaş, Orhan , Kim, Ho Jin , Paul, Friedemann , Pittock, Sean J, Weinshenker, Brian G. , Wingerchuk, Dean M. , Cutter, Gary , Patra, Kaushik, Flor, Armando , Barron, Gerard, Madani, Soraya, Ratchford, John N. , Katz, Eliezer , Pittock, Sean J. , Wingerchuk, Dean, Pittock, S J , Cohen, Jeffrey Allen , Fujihara, Kazuo , Bennett, Jeffrey L , Weinshenker, Brian G , Cree, Bruce Ac , Paul, Friedemann

Multiple Sclerosis Journal | December 14, 2015 | Volume: 22 | Issue: 7 | Pages: 862-872

10.1177/1352458515620934 | PMID 26666258 Get It

Background: To date, no treatment for neuromyelitis optica (NMO) has been granted regulatory approval, and no controlled clinical studies have been reported. Objective: To design a placebo-controlled study in NMO that appropriately balances patient safety and clinical–scientific integrity. Methods: We assessed the “standard of care” for NMO to establish the ethical framework for a placebo-controlled trial. We implemented measures that balance the need for scientific robustness while mitigating the risks associated with a placebo-controlled study. The medical or scientific community, patient organizations, and regulatory authorities were engaged early in discussions on this placebo-controlled study, and their input contributed to the final study design. Results: The N-MOmentum study (NCT02200770) is a clinical trial that randomizes NMO patients to receive MEDI-551, a monoclonal antibody that depletes CD19+ B-cells, or placebo. The study design has received regulatory, ethical, clinical, and patient approval in over 100 clinical sites in more than 20 countries worldwide. Conclusion: The approach we took in the design of the N-MOmentum trial might serve as a roadmap for other rare severe diseases when there is no proven therapy and no established clinical development path.
Musclin is an activity-stimulated myokine that enhances physical endurance
Subbotina, Ekaterina , Sierra, Ana , Zhu, Zhiyong , Koganti, Siva, Reyes, Santiago , Stepniak, Elizabeth, Walsh, Susan A. , Acevedo, Michael R., Pérez-Terzic, Carmen, Hodgson‐Zingman, Denice , Zingman, Leonid V. , Perez-Terzic, Carmen M

Proceedings of the National Academy of Sciences | December 14, 2015 | Volume: 112 | Issue: 52 | Pages: 16042-16047

10.1073/pnas.1514250112 | PMID 26668395 Get It

Significance Skeletal muscle is increasingly recognized as a secretory organ. Revealing the identity and function of myokines can improve our understanding of skeletal muscle function under sedentary or exercise conditions, as well as its coordination with other organs, tissues, and overall body metabolism. This study identifies musclin as an exercise-responsive myokine critical for skeletal muscle adaptation to physical activity. We develop a musclin-encoding gene ( Ostn ) knockout mouse, which allows us to determine a previously unrecognized physiologic function of musclin in regulation of skeletal muscle mitochondrial biogenesis and physical endurance. The demonstrated molecular mechanism for musclin-dependent skeletal muscle adaptation to exercise also transforms the perspective on natriuretic peptide signaling, particularly as it relates to physical activity and exercise-induced remodeling in different tissues.
Maternal IL‐6 can cause T‐cell‐mediated juvenile alopecia by non‐scarring follicular dystrophy in mice
Smith, Stephen , Maus, Rachel L.G., Davis, Tessa R. , Gil, Diana , Schrum, Adam G. , Smith, Stephen E P, Sundberg, John P. , Schrum, Adam G

Experimental Dermatology | December 14, 2015 | Volume: 25 | Issue: 3 | Pages: 223-228

10.1111/exd.12914 | PMID 26660334 Get It

AbstractAiming to decipher immunological mechanisms of the autoimmune disorder alopecia areata (AA), we hypothesized that interleukin‐6 (IL‐6) might be associated with juvenile‐onset AA, for which there is currently no experimental model. Upon intramuscular transgenesis to overexpress IL‐6 in pregnant female C57BL/6 (B6) mice, we found that the offspring displayed an initial normal and complete juvenile hair growth cycle, but developed alopecia around postnatal day 18. This alopecia was patchy and reversible (non‐scarring) and was associated with upregulation of Ulbp1 expression, the only mouse homolog of the human AA‐associated ULBP3 gene. Alopecia was also associated with inflammatory infiltration of hair follicles by lymphocytes, including alpha‐beta T cells, which contributed to surface hair loss. Despite these apparently shared traits with AA, lesions were dominated by follicular dystrophy that was atypical of human AA disease, sharing some traits consistent with B6 alopecia and dermatitis. Additionally, juvenile‐onset alopecia was followed by complete, spontaneous recovery of surface hair, without recurrence of hair loss. Prolonging exposure to IL‐6 prolonged the time to recovery, but once recovered, repeating high‐dose IL‐6 exposure de novo did not re‐induce alopecia. These data suggest that although substantial molecular and cellular pathways may be shared, functionally similar alopecia disorders can occur via distinct pathological mechanisms.
Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population‐Based Cohort Study
Gabriel, Sherine E., Wang, Runsheng , Ward, Michael M.

Arthritis & Rheumatology | December 14, 2015 | Volume: 68 | Issue: 6 | Pages: 1415-1421

10.1002/art.39542 | PMID 26663907 Get It

ObjectiveThe long‐term outcome of patients with nonradiographic axial spondyloarthritis (SpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective was to examine the progression to AS in a population‐based inception cohort of patients with nonradiographic axial SpA.MethodsThe Rochester Epidemiology Project (REP) is a longstanding population‐based study of health in the residents of Olmsted County, Minnesota. We searched the REP from 1985 to 2010 using diagnostic and procedural codes for back pain, HLA–B27, and magnetic resonance imaging of the pelvis, and we performed detailed chart reviews to identify subjects who fulfilled the Assessment of SpondyloArthritis international Society classification criteria for axial SpA but did not have AS. We followed these subjects from disease onset to March 15, 2015, and used survival analysis to measure the time to progression to AS.ResultsAfter screening 2,151 patients, we identified 83 subjects with new‐onset nonradiographic axial SpA. Over a mean follow‐up of 10.6 years, progression to AS occurred in 16 patients. The probability that the condition would remain as nonradiographic axial SpA at 5, 10, and 15 years was 93.6%, 82.7%, and 73.6%, respectively. There was more frequent and more rapid progression among subjects in the imaging arm (n = 18) than among those in the clinical arm (n = 65) (28% versus 17%; hazard ratio 3.50 [95% confidence interval 1.15–10.6], P = 0.02).ConclusionProgression to AS occurred in a minority (26%) of patients with nonradiographic axial SpA over as long as 15 years of follow‐up. This suggests that the classification criteria for nonradiographic axial SpA identifies many patients in whom the condition is unlikely to progress to AS or that nonradiographic axial SpA represents a prolonged prodromal state that takes longer to evolve to AS and thus requires longer follow‐up.